Search

How to apply

The CRTH 2025 call for applications are open. Apply now

Questions: training@ehaweb. orgDownload the Signature letter template. Fill in the template and get it duly signed for upload into the online application platform. Access the EHA Portal at http://eha.

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is caused by mutations in the ETV6-gene.

Read more

SWG Educational Activities

EHA2023 Hybrid CongressDate and locationJune 8–11, 2023, in Frankfurt, Germany. ChairMarie Jose Kersten

Case discussions
Follicular Lymphoma: Martin Dreylng, Daphne De Jong. Double hit Lymphoma: Andrew Davies, Elias Campo. T-follicular helper cell lymphoma: Andrew Davies, Daphne De Jong.

Read more

BENIGN HEMATOLOGY in 2023 and beyond

The term "benign hematology" has traditionally been used to refer to non-malignant blood disorders. However, over the past few years, questions have been raised as to the appropriate nomenclature for this category of diseases.

Read more